Abstract
The human cytochrome P450 (CYP) enzyme CYP4Z1 is a fatty acid hydroxylase which among human CYPs is unique for being much stronger expressed in the mammary gland than in all other tissues. Moreover, it is strongly overexpressed in all subtypes of breast cancer, and some overexpression has also been found in other types of malignancies, such as ovarian, lung, and prostate cancers, respectively. Due to its unique expression pattern it is conceivable that this enzymes' activity might be exploited for a new therapeutic approach. However, the main challenge for a CYP4Z1-based prodrug strategy (CBPS) for the treatment of breast cancer (and possibly other CYP4Z1-positive malignancies) is the identification of candidate prodrugs that can be activated by this enzyme. In this mini-review we summarize the current knowledge about the enzymatic properties of the CYP4Z1 enzyme as well as on the expression pattern of the CYP4Z1 gene in both normal and cancer cells. Moreover, we present the first homology model of this enzyme and give an outlook on its potential use in cancer treatment strategies.
Keywords: Breast cancer, CYP4Z1, fatty acid hydroxylation, homology model, monooxygenase, prodrug.
Current Pharmaceutical Design
Title:CYP4Z1 – A Human Cytochrome P450 Enzyme that Might Hold the Key to Curing Breast Cancer
Volume: 23 Issue: 14
Author(s): Xu Yang, Michael Hutter, Wilson Wen Bin Goh and Matthias Bureik*
Affiliation:
- School of Pharmaceutical Science and Technology (SPST), Tianjin University, 92 Weijin Road, Nankai District, Tianjin 300072,China
Keywords: Breast cancer, CYP4Z1, fatty acid hydroxylation, homology model, monooxygenase, prodrug.
Abstract: The human cytochrome P450 (CYP) enzyme CYP4Z1 is a fatty acid hydroxylase which among human CYPs is unique for being much stronger expressed in the mammary gland than in all other tissues. Moreover, it is strongly overexpressed in all subtypes of breast cancer, and some overexpression has also been found in other types of malignancies, such as ovarian, lung, and prostate cancers, respectively. Due to its unique expression pattern it is conceivable that this enzymes' activity might be exploited for a new therapeutic approach. However, the main challenge for a CYP4Z1-based prodrug strategy (CBPS) for the treatment of breast cancer (and possibly other CYP4Z1-positive malignancies) is the identification of candidate prodrugs that can be activated by this enzyme. In this mini-review we summarize the current knowledge about the enzymatic properties of the CYP4Z1 enzyme as well as on the expression pattern of the CYP4Z1 gene in both normal and cancer cells. Moreover, we present the first homology model of this enzyme and give an outlook on its potential use in cancer treatment strategies.
Export Options
About this article
Cite this article as:
Yang Xu, Hutter Michael, Goh Wen Bin Wilson and Bureik Matthias*, CYP4Z1 – A Human Cytochrome P450 Enzyme that Might Hold the Key to Curing Breast Cancer, Current Pharmaceutical Design 2017; 23 (14) . https://dx.doi.org/10.2174/1381612823666170207150156
DOI https://dx.doi.org/10.2174/1381612823666170207150156 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Synthesis, Biological Evaluation and Molecular Docking Study of Cyclic Diarylheptanoids as Potential Anticancer Therapeutics
Anti-Cancer Agents in Medicinal Chemistry Repositioning of DHFR Inhibitors
Current Topics in Medicinal Chemistry Molecular Docking and In Silico ADMET Study Reveals Flavonoids as a Potential Inhibitor of Aromatase
Letters in Drug Design & Discovery Modulation of the TRPV1 Channel: Current Clinical Trials and Recent Patents with Focus on Neurological Conditions
Recent Patents on CNS Drug Discovery (Discontinued) Synthesis of Cyclodextrin Derivatives of Amino-(thiazolyl) Coumarins as Potential Antimicrobial Agents
Letters in Drug Design & Discovery Coumarin Hybrids: Promising Scaffolds in the Treatment of Breast Cancer
Mini-Reviews in Medicinal Chemistry Alzheimer’s Disease and Molecular Chaperones: Current Knowledge and the Future of Chaperonotherapy
Current Pharmaceutical Design Recent Advances in Ginsenosides as Potential Therapeutics Against Breast Cancer
Current Topics in Medicinal Chemistry Hypoglycemic Agents in the Management of Type 2 Diabetes Mellitus
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery The Role of Vitamin D and Sunlight Incidence in Cancer
Anti-Cancer Agents in Medicinal Chemistry <I>Prunus Armeniaca L</I>. Seed Extract and Its Amygdalin Containing Fraction Induced Mitochondrial-Mediated Apoptosis and Autophagy in Liver Carcinogenesis
Anti-Cancer Agents in Medicinal Chemistry Cyclooxygenase-2 Inhibitors as a Therapeutic Target in Inflammatory Diseases
Current Medicinal Chemistry Subject Index To Volume 2
Current Bioactive Compounds Mandatory Reporting of Coronary Artery Calcifications Incidentally Noted on Chest Multi-Detector Computed Tomography: A Multicentre Experience
Current Vascular Pharmacology Nutriproteomics – Linking Proteomics Variation with Personalized Nutrition
Current Pharmacogenomics and Personalized Medicine Post-Exercise Ketosis, Salivary Uric Acid and Interleukin-6 after a Simulated Wheelchair Basketball Match
Endocrine, Metabolic & Immune Disorders - Drug Targets Advances in Peptide Pharmaceuticals
Current Pharmaceutical Biotechnology “Letting the Air In” Can Set the Stage for Tumor Recurrences
Current Cancer Therapy Reviews Progress of Individualized Chemotherapy for Gastric Carcinoma Under the Guidance of Genetic Testing
Current Medicinal Chemistry Fecal Microbiota Transplant: Latest Addition to Arsenal against Recurrent <i>Clostridium difficile</i> Infection
Recent Advances in Anti-Infective Drug Discovery